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the large number of studies. Also much progress has been made
in establishing reliable “responder criteria”, which has further im-
proved the reporting of results of these trials.
Interest has grown in the discovery of drugs and treatment that
can reduce or stop disease progression. A number of treatments
including symptomatic slow-acting drugs in OA (SYSADOA) from
the naturoceutical ﬁeld have demonstrated the capability of some
to reduce the loss of cartilage in knee and hip OA patients. Thus
far, very little is known about the effect of such treatment on
other joint structural changes that take place during the disease
process. In spite of all the progress made in the symptomatic
treatment of OA, the development of new disease modifying OA
drugs (DMOADs) and/or agents is clearly lagging behind and
major advancements are urgently needed. The development of
DMOADs is facing a number of challenges. The ﬁrst one being the
regulatory environment in which the ﬁeld needs an actualization of
the R&D aspect for DMOAD research programs using for instance
recent scientiﬁc advances.
Indeed the actual tools used for the evaluation of disease symp-
toms in long-term DMOAD clinical trials, as well as joint structural
changes, could beneﬁt from being reassessed in light of the re-
sults from recent trials. The impact of DMOAD treatment on the
function and quality of life of OA patients should include a more
global evaluation, including joint structural assessment. This is of
particular importance as the disease symptoms of one particu-
lar joint (target joint) often do not necessarily correlate with the
severity of structural changes.
The reliability and sensitivity of the technology used for joint struc-
ture to assess the effectiveness of treatment urgently need to be
revisited. For instance, X-rays are still recognized as gold standard
by most regulatory agencies for knee or hip DMOAD clinical trials.
It is now well demonstrated that this technique has several sig-
niﬁcant limitations including weak sensitivity to change. Important
progress has been made in the development of technologies in-
cluding MRI which can assess and quantify joint structural changes
occurring in OA and, more speciﬁcally, in the knee and the hip.
MRI can detect disease progression in a much larger percentage
of knee OA patients compared to X-rays and in a shorter time
frame. Furthermore, it is possible when using MRI to document
the role played by a number of risk factors in the progression of the
disease such as meniscal lesions and subchondral bone marrow
lesions. The ﬁrst multicentre DMOAD clinical study done in knee
OA patients with a follow-up of two years using quantitative MRI
was recently completed with the results supporting the superiority
of MRI over X-rays in DMOAD clinical trials.
An additional challenge for DMOAD trials is the need to better
deﬁne the outcome measures. It has been suggested that total
joint replacement of hip or knee could be a valid outcome measure
for structure modifying trials in OA. Different initiatives are now
in progress to deﬁne alternative endpoints to allow its successful
implementation into DMOAD trials. Notions such as “time to joint
replacement” and “virtual joint replacements” are being explored.
Much work remains to be done in improving the design of DMOAD
clinical trials and selecting DMOA drugs and agents. In particular,
a clariﬁcation of study outcomes is an important milestone that
has yet to be achieved.
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Purpose: Epigenetic mechanisms determine cell-type speciﬁc
gene expression and mediate interactions between the environ-
ment and the genome. Two major aspects are DNA methylation
and histone modiﬁcations. Genes that are part of the expression
repertoire of a somatic cell type show DNA hypo-methylation, ac-
tivating histone modiﬁcations such as acetylation, and chromatin
has an open structure. This permits binding of speciﬁc inductive
or repressive factors to the relevant promoters and facilitates rapid
changes in transcription of cell-type speciﬁc genes. Genes that
are never expressed by a particular somatic cell are permanently
silenced by DNA methylation, repressive histone modiﬁcations
and chromatin condensation; this prevents access of the rele-
vant transcription factors to the promoters. During cell division,
the DNA methylation pattern is rapidly reproduced by the mainte-
nance DNA methyl transferase (DNMT1). The histone code can
be re-established by interactions of methyl binding domains and
DNMTs with histone methyltransferases and histone deacetylases
so that both the DNA methylation pattern and the histone code
are reproduced during mitosis.
Methods: DNA methylation is generally stable in somatic cells
throughout adult life and epigenetic disruption may activate nor-
mally silent genes or silence normally expressed genes.
Results: This is precisely the situation in osteoarthritic chon-
drocytes, where many non-chondrocytic genes are permanently
activated. For example, articular chondrocytes normally do not
express cartilage-degrading enzymes or IL-1β, and the promoters
of these genes are heavily methylated. However, loss of methyla-
tion at speciﬁc CpG sites has occurred in chondrocytes from OA
patients (Arthritis & Rheum. 52:3110-24), which enables an ‘unsi-
lencing’ and consequent aberrant expression of non-chondrocytic
genes. This de-methylation was also observed in a 23-year old,
who had osteoarthritis as a consequence of Developmental Dys-
plasia of the Hip, suggesting that DNA de-methylation was not just
a consequence of age, but an integral part of the disease process.
The factors that might cause loss of DNA methylation are still
unknown. We have shown that inﬂammatory cytokines have the
capacity to change DNA methylation status, at least in vitro,
although the exact mechanisms can only be speculated upon.
Conclusions: One can envisage the following scenario in os-
teoarthritis: In the acute phase following injury, inﬂammatory cy-
tokines, produced by cells of an inﬂamed synovium, diffuse into the
cartilage and cause loss of DNA methylation resulting in ‘unsilenc-
ing’ of proteases and IL-1β in chondrocytes of the superﬁcial zone.
In the subsequent chronic phase, cytokines produced by chondro-
cytes diffuse to adjacent chondrocytes and repeat the process. In
this phase, there is no further requirement of synovial cytokines
and the process is self-perpetuating, which may explain the in-
evitable progression of cartilage degradation from the superﬁcial to
the deep zone. If the loss of DNA methylation could be prevented,
then presumably the aberrant induction of non-chondrocytic genes
could be prevented and ultimately the progression of OA might be
slowed down or even halted.
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Once considered a non-inﬂammatory disease of articular cartilage,
osteoarthritis (OA) is now understood to be a complex condition
affecting all joint tissues. Synovial inﬂammation is increasingly
recognized as an important process, however inﬂammation can
be deﬁned in diverse ways: by clinical examination, advanced
imaging techniques, or at the cellular or molecular level by cellular
inﬁltration, soluble mediators, and activated signalling pathways.
Imaging [1] and arthroscopic [2] studies have pointed to the clinical
importance of inﬂammation in OA patients. Evidence emerging at
the cellular and molecular level will be discussed which implicates
activation of the innate immunity.
